Profil
Michelle L.
Mellion formerly worked at Vertex Pharmaceuticals, Inc., as Medical Director from 2016 to 2018, Biogen, Inc., as Associate Medical Director from 2015 to 2016, Fulcrum Therapeutics, Inc., as Executive Medical Director from 2018 to 2022, and PepGen Inc., as Chief Medical Officer from 2024 to 2025.
Dr. Mellion received her doctorate degree from Wake Forest University and undergraduate degree from Colgate University.
Ehemalige bekannte Positionen von Michelle Mellion
| Unternehmen | Position | Ende |
|---|---|---|
| PEPGEN INC. | Technik-/Wissenschafts-/F&E-Leiter | 04.04.2025 |
| FULCRUM THERAPEUTICS, INC. | Corporate Officer/Principal | 01.03.2022 |
| VERTEX PHARMACEUTICALS INCORPORATED | Technik-/Wissenschafts-/F&E-Leiter | 01.08.2018 |
| BIOGEN INC. | Corporate Officer/Principal | 01.11.2016 |
Ausbildung von Michelle Mellion
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 6 |
|---|---|
Vertex Pharmaceuticals, Inc.
Vertex Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Operates as a pharmaceutical company that develops drugs for the treatment of cystic fibrosis | Health Technology |
Biogen, Inc.
Biogen, Inc. Pharmaceuticals: MajorHealth Technology Manufactures and markets therapies for neurological and neurodegenerative diseases | Health Technology |
Wake Forest University
Wake Forest University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Colgate University
Colgate University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Fulcrum Therapeutics, Inc.
Fulcrum Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops medicines for patients by transforming gene regulation in disease | Health Technology |
PepGen Inc.
PepGen Inc. BiotechnologyHealth Technology Operates as clinical stage biotechnology company which develops oligonucleotide therapeutics for treatment of severe neuromuscular and neurologic diseases | Health Technology |
















